Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pfizer
Eli Lilly and Company
Pfizer
Pfizer
SWOG Cancer Research Network
Institut du Cancer de Montpellier - Val d'Aurelle